To include your compound in the COVID-19 Resource Center, submit it here.

Novartis' Gilenya meets in Phase III for pediatric MS

Novartis AG (NYSE:NVS; SIX:NOVN) reported top-line data from the Phase III PARADIGMS trial in 215 patients ages 10-17 with multiple sclerosis

Read the full 215 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE